Morotti, Andrea http://orcid.org/0000-0002-6558-1155
,
Shoamanesh, Ashkan
Oliveira-Filho, Jamary
Schlunk, Frieder
Romero, Javier M.
Jessel, Michael
Ayres, Alison
Vashkevich, Anastasia
Schwab, Kristin
Cassarly, Christy
Martin, Renee’ Hebert
Greenberg, Steven M.
Qureshi, Adnan I.
Rosand, Jonathan
Goldstein, Joshua N.
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (5R01NS073344)
Article History
First Online: 19 June 2019
Conflict of interest
: Andrea Morotti reports no disclosures. Ashkan Shoamanesh reports research funding from Bristol-Myer Squibb, Bayer AG and Servier Canada Inc., and consulting from Apopharma Inc., Bayer AG, Daiichi Sankyo, Servier Canada Inc., Bristol-Myer Squibb and Boehringer Ingelheim. Jamary Oliveira-Filho reports no disclosures. Frieder Schlunk reports no disclosures. Javier M. Romero reports no disclosures. Michael Jessel reports no disclosures. Alison Ayres reports no disclosures. Anastasia Vashkevich reports no disclosures. Kristin Schwab reports no disclosures. Christy Cassarly reports no disclosures. Renee’ Hebert Martin reports no disclosures. Steven M. Greenberg reports no disclosures. Adnan I. Qureshi reports no disclosures. Jonathan Rosand reports consulting for Pfizer, Boehringer Ingelheim. Joshua Goldstein reports research funding from Pfizer, Portola, and consulting from CSL Behring, Octapharma, Phillips.
: Local Institutional Review Boards approval was obtained at all ATACH-2 enrolling sites, and informed consent was obtained from all participants.